Reichstag building in Berlin, Photo by Jürgen Matern

The International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress took place July 7-13 in Berlin, Germany.

Product can reduce, prevent bleeding in kids with FXD

Print Friendly, PDF & Email

Vials and a syringe
Results of a phase 3 study suggest prophylaxis with plasma-derived factor X (pdFX, Coagadex®) prevents or reduces bleeding episodes in children with moderate to severe hereditary factor X deficiency (FXD). pdFX was well tolerated in this study as well, with no treatment-related adverse events (AEs) reported. “For the first... [Read Article]
Print Friendly, PDF & Email

Death is most frequent major adverse outcome after VTE

Print Friendly, PDF & Email

Patient takes anticoagulant
after knee surgery
Photo courtesy of
Boehringer Ingelheim
Data from the GARFIELD-VTE registry showed that, in the first 6 months after a patient was diagnosed with venous thromboembolism (VTE), death was the most frequent major adverse outcome. More than half of the deaths were related to cancer, with small... [Read Article]
Print Friendly, PDF & Email

Idarucizumab reverses effects of dabigatran in emergencies

Print Friendly, PDF & Email

Team performing surgery
Photo by Piotr Bodze
Final results from the RE-VERSE AD trial suggest idarucizumab can reverse the anticoagulant effect of dabigatran etexilate mesylate in emergency situations. Patients who required dabigatran reversal because they needed urgent surgery were able to have their procedure a median of 1.6 hours from idarucizumab administration. In... [Read Article]
Print Friendly, PDF & Email

Antibody reduces bleeding in hemophilia A patients with inhibitors

Print Friendly, PDF & Email

Monoclonal antibodies
Photo by Linda Bartlett
Emicizumab can reduce bleeding in adults and adolescents with hemophilia A and inhibitors to factor VIII, according to a phase 3 trial. In the HAVEN 1 trial, prophylaxis with emicizumab reduced the treated bleed rate by 87% when compared to no prophylaxis. Emicizumab reduced the treated... [Read Article]
Print Friendly, PDF & Email